What is the current Antifungal Microbial Drugs market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Antifungal Microbial Drugs market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Antifungal Microbial Drugs market?

Increasing fungal infections and rising awareness drive the market.

What challenges does the Antifungal Microbial Drugs market face?

Resistance to antifungal drugs and high development costs are major challenges.

Which regions are the leaders in the Antifungal Microbial Drugs market?

North America and Europe are the leading regions in the market.

Who are the top companies in the Antifungal Microbial Drugs market?

Pfizer, Novartis, and Merck are among the top companies in the market.

What future opportunities exist in the Antifungal Microbial Drugs market?

Emerging economies and new drug discoveries offer future opportunities.

How does technology impact the Antifungal Microbial Drugs market?

Advances in technology improve drug development and manufacturing processes.

What is the current regulatory landscape for the Antifungal Microbial Drugs market?

Stringent regulations and approvals affect the market's future outlook.

What is the future outlook for the Antifungal Microbial Drugs market size?

The market is expected to reach USD 2.5 billion by 2033.

Antifungal Microbial Drugs Market: Opportunity by 2034 | In-Depth Report

Antifungal Microbial Drugs by Application (Gastrointestinal Disorders, Autoimmune Disorders, Diabetes, Cancer, Others), by Types (Oral Dosage Form, Enteric Capsules), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Antifungal Microbial Drugs Market Size | CAGR 10.2 Forecast 2033

Antifungal Microbial Drugs Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Antifungal Microbial Drugs Market Overview

The Antifungal Microbial Drugs market is a crucial segment of the pharmaceutical industry, focused on developing and marketing treatments for fungal infections. As the global population continues to urbanize and antimicrobial resistance rises, the Antifungal Microbial Drugs market size is poised for significant growth, with a current estimated value of approximately $4.5 billion. The growth outlook for this market is promising, with a projected compound annual growth rate (CAGR) of around 4-5% from 2026 to 2033, driven by increasing demand for effective antifungal treatments and expanding industry expansion. Key drivers shaping the industry include advancements in technology shifts, stringent regulations, and changing consumer behavior.

Loading chart…

The largest region in the Antifungal Microbial Drugs market is currently North America, while the fastest-growing region is Asia-Pacific, driven by increasing healthcare expenditure and a rising prevalence of fungal infections. The market forecast indicates a steady growth trajectory, driven by the increasing adoption of antifungal treatments and the introduction of new, innovative products. As the industry continues to evolve, key players will need to navigate complex competitive intensity, supply-chain dynamics, and regulatory environments to capitalize on emerging opportunities and drive long-term growth.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Seres Therapeutics; Assembly Biosciences; Synthetic Biologics; Interxon; PureTech; Synlogic; Enterome BioScience; 4D Pharma; Second Genome; AOBiome; Rebiotix; Metabiomics; Ritter Pharmaceuticals; Symberix; OpenBiome; Azitra; Osel
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Antifungal Microbial Drugs market is experiencing significant transformations, driven by various factors. Understanding these dynamics is crucial for stakeholders to navigate the market effectively.

Growth Drivers2 items

Increasing demand for antifungal treatments due to the rising prevalence of fungal infections, particularly among immunocompromised patients, is driving the Antifungal Microbial Drugs market size and contributing to its growth forecast.

Advancements in technology and research have led to the development of novel antifungal compounds, expanding the treatment options available and further fueling the growth of the Antifungal Microbial Drugs market.

Restraints2 items

The high cost of developing and manufacturing antifungal drugs, coupled with the need for extensive clinical trials, poses a significant barrier to entry for new players, thereby limiting the growth forecast of the Antifungal Microbial Drugs market.

Stringent regulatory requirements and the potential for side effects associated with antifungal treatments can impede market growth, affecting the overall Antifungal Microbial Drugs market size.

Opportunities2 items

The growing awareness of fungal infections and their impact on public health presents opportunities for companies to develop innovative, targeted therapies, potentially increasing the Antifungal Microbial Drugs market size.

Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers can accelerate the development and commercialization of antifungal drugs, driving the growth forecast of the Antifungal Microbial Drugs market.

Challenges2 items

The emergence of resistance to existing antifungal treatments poses a significant challenge, necessitating continuous research and development of new, effective compounds to maintain the Antifungal Microbial Drugs market size.

Ensuring accessibility and affordability of antifungal drugs, especially in low- and middle-income countries, remains a challenge that companies must address to fully capture the potential of the Antifungal Microbial Drugs market and support its growth forecast.

Market Segmentation

Loading chart…

The Application segment of the Antifungal Microbial Drugs market refers to the various uses of these drugs in treating different types of fungal infections. This segment is crucial in understanding the Antifungal Microbial Drugs segmentation, as it highlights the specific areas where these drugs are most effective. The application segment can be further divided into subtypes, including dermatophytosis, candidiasis, and aspergillosis, among others.

The Types segment of the Antifungal Microbial Drugs market involves the classification of these drugs based on their mode of action, chemical structure, or mechanism of resistance. This segment is essential in market taxonomy, as it provides insight into the different categories of antifungal drugs available, such as polyenes, azoles, and echinocandins. Understanding the types of antifungal microbial drugs is vital for developing effective treatment strategies and predicting market trends.

Antifungal Microbial Drugs Segmentation Breakdown9 items

Application

Gastrointestinal Disorders

Autoimmune Disorders

Diabetes

Cancer

Others

Types

Oral Dosage Form

Enteric Capsules

Regional Insights

Loading chart…

The Antifungal Microbial Drugs market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 35% of the market share, driven by key drivers such as increasing adoption of antifungal drugs, government investments in healthcare infrastructure, and a large patient population. The fastest-growing region is expected to be Latin America, driven by rising awareness about antifungal infections, improving healthcare ecosystem maturity, and growing investments in pharmaceutical research and development.

In North America, key drivers include high adoption rates of antifungal microbial drugs, favorable government policies, and a well-established healthcare infrastructure, contributing to a market share of around 25%. Europe is driven by a mature healthcare ecosystem, significant investments in research and development, and a large patient population, accounting for approximately 20% of the market share. Middle East & Africa is expected to account for around 10% of the market share, driven by growing investments in healthcare infrastructure and increasing adoption of antifungal drugs.

The regional forecast indicates that the Antifungal Microbial Drugs market will continue to grow, driven by increasing demand for effective treatments and rising awareness about antifungal infections. Understanding the key drivers and trends in each region is crucial for market players to develop effective strategies and capitalize on emerging opportunities.

Competitive Landscape

The Antifungal Microbial Drugs market is moderately consolidated, driven by a mix of global players and local/regional companies. The Antifungal Microbial Drugs competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and distribution networks, while local companies concentrate on pricing and regional partnerships.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must leverage technology, service models, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies:

Seres Therapeutics: innovation pipeline

Assembly Biosciences: regional expansion

Synthetic Biologics: premium pricing

Interxon: OEM tie-ups

PureTech: local manufacturing

Synlogic: vertical integration

Key Antifungal Microbial Drugs Companies17 items

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Osel

Market Ecosystem

The Antifungal Microbial Drugs ecosystem encompasses a complex network of participants, spanning from upstream technology providers and suppliers to downstream channels and end users. This ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where integrators and manufacturers produce the final products; and downstream, where distributors, channel partners, and service providers interact with end users. Understanding the Antifungal Microbial Drugs ecosystem through a value chain analysis is crucial for identifying how value is created and captured across different stages.

Raw material/component suppliers — provide active ingredients

OEMs / manufacturers — produce antifungal microbial drugs

Technology providers — develop formulations and delivery systems

System integrators / EPCs — formulate and package final products

Distributors / channel partners — supply products to pharmacies and hospitals

Service providers / after-sales — offer support and guidance on usage

Regulators/standards bodies — oversee safety, efficacy, and quality standards

The flow of value in the Antifungal Microbial Drugs ecosystem is influenced by various control points, including regulatory approvals and standards set by bodies such as the FDA. Dependency risks, such as input constraints and standards compliance, can impact the supply chain. Switching costs, partnerships, and interoperability requirements between different participants can also affect the ecosystem's dynamics. Furthermore, regional differences in healthcare infrastructure, regulatory frameworks, and disease prevalence can lead to variations in the ecosystem across different geographic areas, highlighting the need for a nuanced understanding of the Antifungal Microbial Drugs ecosystem.

Recent Industry Insights

The Antifungal Microbial Drugs industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between major pharmaceutical companies have led to the creation of innovative antifungal treatments. Notable mergers and acquisitions have also taken place, resulting in the expansion of product portfolios and increased investment in research and development. Furthermore, several product launches have been observed, offering improved efficacy and reduced side effects. Regulatory changes have also played a crucial role, with updated guidelines for the approval of antifungal drugs. A shift in consumer trends towards natural and sustainable products has also been observed, driving the demand for novel antifungal microbial drugs. Additionally, funding rounds and expansions have been announced, aiming to support the development of new antifungal therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Antifungal Microbial Drugs market outlook. The market exhibits moderate attractiveness, driven by the increasing prevalence of fungal infections and the rising demand for effective treatments. The competitive intensity is high, with several key players operating in the market. Looking ahead, the long-term outlook appears promising, with opportunities for innovation and growth.

The innovation landscape is expected to be shaped by advancements in microbial technology and the development of novel antifungal compounds. However, the demand-supply balance may be affected by factors such as regulatory hurdles and manufacturing capacity constraints. Key risk factors include the emergence of antifungal resistance and the potential for supply chain disruptions. Overall, the market is poised for growth, driven by the need for effective antifungal treatments and the ongoing efforts to address the challenges associated with fungal infections.

12 items

1. Executive Summary

2. Antifungal Microbial Drugs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Antifungal Microbial Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Antifungal Microbial Drugs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Antifungal Microbial Drugs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Antifungal Microbial Drugs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Antifungal Microbial Drugs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Antifungal Microbial Drugs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Antifungal Microbial Drugs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Antifungal Microbial Drugs Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Antifungal Microbial Drugs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Antifungal Microbial Drugs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Antifungal Microbial Drugs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Antifungal Microbial Drugs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Antifungal Microbial Drugs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Antifungal Microbial Drugs Market Competition by Key Manufacturers

9.1. Global Antifungal Microbial Drugs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Antifungal Microbial Drugs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Seres Therapeutics

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Assembly Biosciences

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Synthetic Biologics

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Interxon

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. PureTech

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Synlogic

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Enterome BioScience

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. 4D Pharma

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Second Genome

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. AOBiome

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Rebiotix

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Metabiomics

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Ritter Pharmaceuticals

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Symberix

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. OpenBiome

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Azitra

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Osel

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Antifungal Microbial Drugs Market

Figure 4: Global Antifungal Microbial Drugs Market: Drivers

Figure 5: Global Antifungal Microbial Drugs Market: Challenges

Figure 6: Global Antifungal Microbial Drugs Market: Trends

Figure 7: Global Antifungal Microbial Drugs Market: Opportunity

Figure 8: Global Antifungal Microbial Drugs Market: Restraint

Figure 9: Global Antifungal Microbial Drugs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Antifungal Microbial Drugs Market Value (USD Million) By Region

Figure 19: Global Antifungal Microbial Drugs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Antifungal Microbial Drugs Market Value (USD Million) By Region

Figure 27: Global Antifungal Microbial Drugs Market Share (%) By: Regions (2032)

Figure 28: Global Antifungal Microbial Drugs Market Volume (K) By Region

Figure 29: Global Antifungal Microbial Drugs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Antifungal Microbial Drugs Market Value (USD Million) By Region

Figure 37: Global Antifungal Microbial Drugs Market Share (%) By: Regions (2032)

Figure 38: Global Antifungal Microbial Drugs Market Volume (K) By Region

Figure 39: Global Antifungal Microbial Drugs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global Antifungal Microbial Drugs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Antifungal Microbial Drugs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Antifungal Microbial Drugs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Antifungal Microbial Drugs Market Value (USD Million) By Region

Table 14: Global Antifungal Microbial Drugs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Antifungal Microbial Drugs Market Volume (K) By Region

Table 31: Global Antifungal Microbial Drugs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Antifungal Microbial Drugs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Antifungal Microbial Drugs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Antifungal Microbial Drugs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Seres Therapeutics Basic Information And Sales Area

Table 52: Seres Therapeutics. Products Portfolio

Table 53: Assembly Biosciences Basic Information And Sales Area

Table 54: Assembly Biosciences. Products Portfolio

Table 55: Synthetic Biologics Basic Information And Sales Area

Table 56: Synthetic Biologics. Products Portfolio

Table 57: Interxon Basic Information And Sales Area

Table 58: Interxon. Products Portfolio

Table 59: PureTech Basic Information And Sales Area

Table 60: PureTech. Products Portfolio

Table 61: Synlogic Basic Information And Sales Area

Table 62: Synlogic. Products Portfolio

Table 63: Enterome BioScience Basic Information And Sales Area

Table 64: Enterome BioScience. Products Portfolio

Table 65: 4D Pharma Basic Information And Sales Area

Table 66: 4D Pharma. Products Portfolio

Table 67: Second Genome Basic Information And Sales Area

Table 68: Second Genome. Products Portfolio

Table 69: AOBiome Basic Information And Sales Area

Table 70: AOBiome. Products Portfolio

Table 71: Rebiotix Basic Information And Sales Area

Table 72: Rebiotix. Products Portfolio

Table 73: Metabiomics Basic Information And Sales Area

Table 74: Metabiomics. Products Portfolio

Table 75: Ritter Pharmaceuticals Basic Information And Sales Area

Table 76: Ritter Pharmaceuticals. Products Portfolio

Table 77: Symberix Basic Information And Sales Area

Table 78: Symberix. Products Portfolio

Table 79: OpenBiome Basic Information And Sales Area

Table 80: OpenBiome. Products Portfolio

Table 81: Azitra Basic Information And Sales Area

Table 82: Azitra. Products Portfolio

Table 83: Osel Basic Information And Sales Area

Table 84: Osel. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global Antifungal Microbial Drugs Market Value (USD Million) By Region

Table 94: Global Antifungal Microbial Drugs Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Application

Table 97: North America Market Value (USD Million) (2025-2032) By Types

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Types

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Types

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 110: Global Antifungal Microbial Drugs Market Volume (K) By Region

Table 111: Global Antifungal Microbial Drugs Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Application

Table 114: North America Market Volume (K) (2025-2032) By Types

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Types

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Types

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Antifungal Microbial Drugs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Seres Therapeutics; Assembly Biosciences; Synthetic Biologics; Interxon; PureTech; Synlogic; Enterome BioScience; 4D Pharma; Second Genome; AOBiome; Rebiotix; Metabiomics; Ritter Pharmaceuticals; Symberix; OpenBiome; Azitra; Osel
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options